Statera BioPharma (STAB)

Statera BioPharma (STAB) Stock Price & Analysis


STAB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.01 - $0.31
Previous Close$0.04
Average Volume (3M)351.55K
Market Cap
Enterprise Value$9.47M
Total Cash (Recent Filing)$506.10K
Total Debt (Recent Filing)$7.41M
Price to Earnings (P/E)>-0.1
Aug 14, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding54,661,890
10 Day Avg. Volume225,528
30 Day Avg. Volume351,551
Standard Deviation0.84
Financial Highlights & Ratios
Price to Book (P/B)-0.09
Price to Sales (P/S)2.85
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.50
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.13
Enterprise Value/Gross Profit9.48
Enterprise Value/Ebitda-0.43
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Statera BioPharma’s price range in the past 12 months?
Statera BioPharma lowest stock price was $0.01 and its highest was $0.31 in the past 12 months.
    What is Statera BioPharma’s market cap?
    Currently, no data Available
    When is Statera BioPharma’s upcoming earnings report date?
    Statera BioPharma’s upcoming earnings report date is Aug 14, 2023 which is in 67 days.
      How were Statera BioPharma’s earnings last quarter?
      Statera BioPharma released its earnings results on Nov 14, 2022. The company reported -$0.067 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.067.
        Is Statera BioPharma overvalued?
        According to Wall Street analysts Statera BioPharma’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Statera BioPharma pay dividends?
          Statera BioPharma does not currently pay dividends.
          What is Statera BioPharma’s EPS estimate?
          Statera BioPharma’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Statera BioPharma have?
          Statera BioPharma has 71,416,040 shares outstanding.
            What happened to Statera BioPharma’s price movement after its last earnings report?
            Statera BioPharma reported an EPS of -$0.067 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
              Which hedge fund is a major shareholder of Statera BioPharma?
              Currently, no hedge funds are holding shares in STAB


              Statera BioPharma Stock Smart Score

              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              Statera BioPharma

              Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.


              Forecast EPS vs Actual EPS

              Similar Stocks
              Price & Change
              Acer Therapeutics
              Aytu BioScience
              Bio-Path Holdings

              Popular Stocks

              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis